

Daftar Pustaka

- Achkar IW, Bhat AA, Zafar M, et al. Oncogenic role of dysregulated leptin signaling in the pathogenesis of ovarian cancer (2019). *Translational Medicine Communications*. doi:10.1186/s41231-018-0031-2
- Assidi, M., Yahya, F. M., Al-Zahrani, M. H., Elkhatab, R., Zari, A., Elaimi, A., Al-Maghrabi, J., Dallol, A., Buhmeida, A., & Abu-Elmagd, M. (2021, November 28). Leptin Protein Expression and Promoter Methylation in Ovarian Cancer: A Strong Prognostic Value with Theranostic Promises. *International Journal of Molecular Sciences*, 22(23), 12872. <https://doi.org/10.3390/ijms222312872>
- Banet, N., & Kurman, R. J. (2015). Two Types of Ovarian Cortical Inclusion Cysts. *International Journal of Gynecological Pathology*, 34(1), 3–8. <https://doi.org/10.1097/pgp.0000000000000120>
- Board, W. H. O. C. W. C. O. T. E., & Editorial, W. C. O. T. (2020). *Female genital tumours: WHO classification of tumours*.
- Brown, K. A., & Scherer, P. E. (2023). Update on adipose tissue and cancer. *Endocrine Reviews*. <https://doi.org/10.1210/edrev/bnad015>
- Budijanto, D., Pangribowo, S. and et al, 2019. Infodatin Beban Kanker Di Indonesia. Jakarta: Kementerian Kesehatan RI.
- Catteau, A.; Caillon, H.; Barrière, P.; Denis, M.G.; Masson, D.; Fréour, T. (2015). Leptin and its potential interest in assisted reproduction cycles. *Human Reproduction Update*, (), dmv057–. doi:10.1093/humupd/dmv057
- Chou, S. H., & Mantzoros, C. (2014). 20 YEARS OF LEPTIN: Role of leptin in human reproductive disorders. *Journal of Endocrinology*, 223(1), T49–T62. <https://doi.org/10.1530/joe-14-0245>
- Craig ER, Londoño AI, Norian LA et al. Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review. *Gynecol Oncol*. 2016;143:674-83.
- Dixon SC, Nagle CM, Thrift AP et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *Int J Epidemiol*. 2016;45:884-95.
- Facg, F. F. M. J. G. R., Md, L. L. W., Md, M. J., & Md, J. M. L. (2017b). *Rosai and Ackerman's Surgical Pathology - 2 Volume Set* (11th ed.). Elsevier
- Fernandez ML, Dawson A, Kim H, et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. *Gynecologic Oncology*. 2020;157(1):12-20. doi:10.1016/j.ygyno.2019.11.029
- Ghasemi, Ahmad; Hashemy, Seyed Isaac; Aghaei, Mahmoud; Panjehpour, Mojtaba (2017). RhoA/ROCK pathway mediates leptin-induced uPA expression to promote cell invasion in ovarian cancer cells. *Cellular Signalling*, 32(), 104–114. doi:10.1016/j.cellsig.2017.01.020 (Ghasemi et al.,2017)
- Hoffman, B., Schorge, J., Bradshaw, K., Halvorson, L., Schaffer, J., & Corton, M. (2016). *Williams Gynecology*, Third Edition (3rd ed.). McGraw Hill / Medical.

- Hoffmann M, Fiedor E, Ptak A. 17 B-Estradiol reverses Leptin-Inducing ovarian cancer cell migration by the PI3K/AKT signaling pathway (2016). *Reproductive Sciences*. ;23(11):1600-1608. doi:10.1177/1933719116648214
- Jiménez-Cortegana, C., López-Saavedra, A., Sánchez-Jiménez, F., Pérez-Pérez, A., Castiñeiras, J., Virizuela-Echaburu, J. A., de la Cruz-Merino, L. D. L., & Sánchez-Margalet, V. (2021). Leptin, Both Bad and Good Actor in Cancer. *Biomolecules*, 11(6), 913. <https://doi.org/10.3390/biom11060913> (Jiménez-Cortegana et al., 2021)
- Kato S, Abarzua-Catalan L, Trigo C et al. Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. *Oncotarget*. 2015;6:21100-19.
- Khristian, E., & Inderiati, D. (2017). Bahan Ajar Teknologi Laboratorium Medis (TLM) Sitohistoteknologi. Badan Pengembangan Dan Pemberdayaan Sumber Daya Manusia Kesehatan. Kemenkes RI.
- Kierszenbaum, Abraham L. Et Al. Histology And Cell Biology. An Introduction To Pathology. Fourth Edition. Elsevier 2016.
- Koshiyama, M., Matsumura, N., & Konishi, I. (2014). Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. *BioMed Research International*, 2014, 1–11. <https://doi.org/10.1155/2014/934261>
- Kumar J, Fang H, McCulloch DR et al. Leptin receptor signaling via Janus kinase 2/Signal transducer and activator of transcription 3 impacts on ovarian cancer cell phenotypes. *Oncotarget*. 2017;8:93530-40.
- Kumar, v., Abbas, A. and Aster, J., 2021. Robbins & Cotran Pathologic Basic of Disease. 10th ed. New York: Elsevier. (Kumar, Abbas and Aster, 2021)
- Lennon, H., Sperrin, M., Badrick, E., & Renehan, A. G. (2016). The Obesity Paradox in Cancer: a Review. *Current oncology reports*, 18(9), 56. <https://doi.org/10.1007/s11912-016-0539-4>
- Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, Yoo KH, Jung KS, Kim YK, Rhee CK. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2017 Aug 21;12:2465-2475. doi: 10.2147/COPD.S141295. PMID: 28860741; PMCID: PMC5571887.
- Lin, X., & Li, H. (2021). Obesity: Epidemiology, Pathophysiology, and Therapeutics. *Frontiers in Endocrinology*, 12.
- Mahmood, N., Mihalciou, C., & Rabbani, S. A. (2018). Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. *Frontiers in Oncology*, 8. <https://doi.org/10.3389/fonc.2018.00024>
- Mantzoros, C. S.; Magkos, F.; Brinkoetter, M.; Sienkiewicz, E.; Dardeno, T. A.; Kim, S.-Y.; Hamnvik, O.-P. R.; Koniaris, A. (2011). Leptin in human physiology and pathophysiology. *AJP: Endocrinology and Metabolism*, 301(4), E567–E584. doi:10.1152/ajpendo.00315.2011

- Münzberg, H., & Morrison, C. D. (2015). Structure, production and signaling of leptin. *Metabolism*, 64(1), 13–23. <https://doi.org/10.1016/j.metabol.2014.09.010>
- Navarro, V. M., Gottsch, M. L., Chavkin, C., Okamura, H., Clifton, D. K., & Steiner, R. A. (2009). Regulation of Gonadotropin-Releasing Hormone Secretion by Kisspeptin/Dynorphin/Neurokinin B Neurons in the Arcuate Nucleus of the Mouse. *Journal of Neuroscience*, 29(38), 11859–11866. <https://doi.org/10.1523/jneurosci.1569-09.2009>
- Nucci, M. R., & Parra-Herran, C. (2019). *Gynecologic Pathology E-Book: A Volume in the Series: Foundations in Diagnostic Pathology*. Elsevier Gezondheidszorg.
- Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. *Nutr Today*. 2015 May;50(3):117-128. doi: 10.1097/NT.0000000000000092. Epub 2015 Apr 7. PMID: 27340299; PMCID: PMC4890841.
- Obesity and overweight. (2021b, June 9). World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (Obesity and Overweight, 2021b)
- Olsen CM, Nagle CM, Whiteman DC et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocr Relat Cancer*. 2013;20:251- 62.
- Paik, S. S., Jang, S. O., Jang, K., Lee, K. H., Choi, D., & Jang, S. J. (2008). Leptin Expression Correlates with Favorable Clinicopathologic Phenotype and Better Prognosis in Colorectal Adenocarcinoma. *Annals of Surgical Oncology*, 16(2), 297–303. <https://doi.org/10.1245/s10434-008-0221-7>
- Pati, S., Irfan, W., Jameel, A. T., Ahmed, S., & Shahid, R. (2023). Obesity and Cancer: A Current overview of epidemiology, pathogenesis, outcomes, and management. *Cancers*, 15(2), 485. <https://doi.org/10.3390/cancers15020485>
- Prawirohardjo, S. (2010). *Ilmu kebidanan* (4th ed.). Yayasan Bina Pustaka.
- Ray A, Fornsaglio J, Dogan S, Hedau S, Naik D, De A. Gynaecological cancers and leptin: A focus on the endometrium and ovary. *Facts Views Vis Obgyn*. 2018 Mar;10(1):5-18. PMID: 30510663; PMCID: PMC6260667.
- Ray, A., & Cleary, M. P. (2017). The potential role of leptin in tumor invasion and metastasis. *Cytokine & Growth Factor Reviews*, 38, 80–97. <https://doi.org/10.1016/j.cytogfr.2017.11.002>
- Ray, I., Meira, L. B., Michael, A., & Ellis, P. E. (2022). Adipocytokines and disease progression in endometrial cancer: a systematic review. *Cancer metastasis reviews*, 41(1), 211–242. <https://doi.org/10.1007/s10555-021-10002-6>
- Robertson SA, Leininger GM, Myers MGJ. Molecular and neural mediators of leptin action. *Physiol Behav* 2008;94:637–642.
- Ross A.C., Caballero B., Cousins R.J., Tucker K.L., Ziegler T.R. 2014. *Modern nutrition in health and disease: Eleventh edition*. Lippincott Williams & Wilkins *Modern Nutrition in Health and Disease: Eleventh Edition*, , pp. 1-1616. Schulte,M et al. *Atlas of Anatomy-Latin Nomenclature*. Thieme Medical Publishers, Inc.2009

- Serous cystadenoma / adenofibroma. (2021b, October 25). PathologyOutlines.Com, Inc. <https://www.pathologyoutlines.com/topic/ovarytumorserousbenign.html>
- Sherwood, L. (2015). *Human Physiology: From Cells to Systems* (9th ed.). Cengage Learning.
- Skorupskaite, K., George, J. T., & Anderson, R. A. (2014). The kisspeptin-GnRH pathway in human reproductive health and disease. *Human Reproduction Update*, 20(4), 485–500. <https://doi.org/10.1093/humupd/dmu009>
- The American Cancer Society medical and editorial content team. (2022, January 12). American Cancer Society | Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin. American Cancer Society. Retrieved March 3, 2022, from <https://www.cancer.org/>
- The International Agency for Research on Cancer (IARC). (2021, March). Global Cancer Observatory- GLOBOCAN Indonesia 2020. <https://gco.iarc.fr/>. Retrieved March 3, 2022, from <https://gco.iarc.fr/>
- The Union for International Cancer Control team. (2018, September 12). Global Cancer Data: GLOBOCAN 2018. UICC. Retrieved March 3, 2022, from <https://www.uicc.org/news/global-cancer-data-globocan-2018>
- Thompson, K. J., Lau, K. N., Johnson, S., Martinie, J. B., Iannitti, D. A., McKillop, I. H., & Sindram, D. (2011). *Leptin inhibits hepatocellular carcinoma proliferation via p38-MAPK-dependent signalling*. *HPB*, 13(4), 225–233. doi:10.1111/j.1477-2574.2010.00259.x
- Toro, A. R., Maymó, J. L., Ibarbalz, F. M., Pérez-Pérez, A., Maskin, B., Faletti, A. G., Sánchez-Margalet, V., & Varone, C. L. (2014). Leptin is an anti-apoptotic effector in placental cells involving p53 downregulation. *PloS one*, 9(6), e99187. <https://doi.org/10.1371/journal.pone.0099187>
- Tumminia, A., Vinciguerra, F., Parisi, M., Graziano, M., Sciacca, L., Baratta, R., & Frittitta, L. (2019). Adipose tissue, obesity and adiponectin: Role in endocrine cancer risk. *International Journal of Molecular Sciences*, 20(12), 2863. <https://doi.org/10.3390/ijms20122863>
- Uddin S, Bu R, Ahmed M et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. *Mol Cancer*. 2009;8:74
- Voutsadakis, I. A. (2021). A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 256, 172–178. doi:10.1016/j.ejogrb.2020.11.021
- Wołodko, K., Castillo-Fernandez, J., Kelsey, G., & Galvão, A. (2021). Revisiting the Impact of Local Leptin Signaling in Folliculogenesis and Oocyte Maturation in Obese Mothers. *International Journal of Molecular Sciences*, 22(8), 4270. <https://doi.org/10.3390/ijms22084270>
- Zhang Y, Liu L, Li C, Ai H. Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer. *Cancer Biomark*. 2014; 14:353–359. DOI: 10.3233/CBM-140415 [PubMed: 25171477] (Zhang et al., 2014)

Zvezdaryk, K. J., Sullivan, D. E., & Saifudeen, Z. (2018). The p53/Adipose-Tissue/Cancer Nexus. *Frontiers in Endocrinology*, 9. <https://doi.org/10.3389/fendo.2018.00457>